Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coya TherapeuticsCOYA -3.10%49 Current Ratio is 13.40 as of Jun. 2026, which is 52% above its 10-year median of 8.79. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued). Among 1,409 Biotechnology companies, Coya Therapeutics ranks better than 84.95% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Coya Therapeutics's current ratio for the quarter that ended in Jun. 2026 was 13.40.
Coya Therapeutics has a current ratio of 13.40. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Coya Therapeutics's Current Ratio or its related term are showing as below:
COYA'
s Current Ratio Range Over the Past 10 Years
Min: 1.88 Med: 8.79 Max: 19.57
Current: 13.4
During the past 6 years, Coya Therapeutics's highest Current Ratio was 19.57. The lowest was 1.88. And the median was 8.79.
COYA's Current Ratio is ranked better than 84.95% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs COYA: 13.40
Coya Therapeutics (NAS:COYA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Coya Therapeutics Current Ratio Related Terms
Coya Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Coya Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COYA vs ONCY, GUTS, SEER: Current Ratio Comparison
For the Biotechnology subindustry, Coya Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coya Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coya Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Coya Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coya Therapeutics (COYA) has a Current Ratio of 13.40 as of Jun. 2026. This is 52% above median its historical median of 8.79. Over the past decade, Coya Therapeutics' Current Ratio has ranged from 1.88 to 19.57. According to the industry distribution chart, Coya Therapeutics ranks #212 out of 1409 companies in the Biotechnology industry, placing it in the top 15%.
Is Coya Therapeutics' Current Ratio too high?
Coya Therapeutics' current Current Ratio of 13.40 is 52% above median its 10-year median of 8.79. Over the past 10 years, this metric has ranged from a low of 1.88 to a high of 19.57. The Biotechnology industry median Current Ratio is 3.89. Coya Therapeutics' value of 13.40 is 244.5% above this industry median. Based on the distribution chart, Coya Therapeutics ranks #212 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' Current Ratio compare to ONCY and GUTS?
According to the Biotechnology industry distribution chart, Coya Therapeutics ranks #212 out of 1409 companies for Current Ratio. This places Coya Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Coya Therapeutics' value of 13.40 is 244.5% above this benchmark. Historically, Coya Therapeutics' own Current Ratio has ranged from 1.88 to 19.57 over the past decade. While the company's 10-year median is 8.79 vs. the industry median of 3.89, Coya Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coya Therapeutics's current Current Ratio of 13.40 is 244.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coya Therapeutics's current Current Ratio is 13.40, which is 52% above median its own 10-year median of 8.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current Current Ratio is 13.40, which is 52% above median its 10-year median of 8.79 and 244.5% above the Biotechnology industry median of 3.89. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current Current Ratio is 13.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coya Therapeutics (COYA) Overvalued in 2026?
Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued.
The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54.
GuruFocus considers Coya Therapeutics to be Significantly Undervalued.
Key valuation signals for COYA:
Current Ratio: 13.40 (52% above median its 10-year median of 8.79)
GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
Industry Position: 244.5% above the Biotechnology median (#212 of 1409)
No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score
Get the complete analysis for COYA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COYA has been successfully added to your 
